Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry Arnason

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Lancet (London, England)|June 5, 2003
Interferons in relapsing remitting multiple sclerosisDon Paty, Barry Arnason, David Li, et al.
Journal of Neurology|March 19, 2013
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND studyChristian Lampl, Stefan Nagl, Barry Arnason, et al.
Journal of Neurology|May 15, 2016
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trialSven Schippling, Paul O'Connor, Volker Knappertz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 29, 2011
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trialDouglas S Goodin, Hans-Peter Hartung, Paul O'Connor, et al.
Journal of Neurology|August 5, 2015
Predictors of disease activity in 857 patients with MS treated with interferon beta-1bHans-Peter Hartung, Ludwig Kappos, Douglas S Goodin, et al.
Clinical Therapeutics|July 22, 2008
Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot studyBarrie J Hurwitz, Douglas Jeffery, Barry Arnason, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2018
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trialsDorothea Buck, Till Fm Andlauer, Wilmar Igl, et al.
The Lancet. Neurology|September 5, 2009
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O'Connor, Massimo Filippi, Barry Arnason, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Lancet (London, England)|June 5, 2003
Interferons in relapsing remitting multiple sclerosisDon Paty, Barry Arnason, David Li, et al.
Journal of Neurology|March 19, 2013
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND studyChristian Lampl, Stefan Nagl, Barry Arnason, et al.
Journal of Neurology|May 15, 2016
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trialSven Schippling, Paul O'Connor, Volker Knappertz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 29, 2011
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trialDouglas S Goodin, Hans-Peter Hartung, Paul O'Connor, et al.
Journal of Neurology|August 5, 2015
Predictors of disease activity in 857 patients with MS treated with interferon beta-1bHans-Peter Hartung, Ludwig Kappos, Douglas S Goodin, et al.
Clinical Therapeutics|July 22, 2008
Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot studyBarrie J Hurwitz, Douglas Jeffery, Barry Arnason, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2018
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trialsDorothea Buck, Till Fm Andlauer, Wilmar Igl, et al.
The Lancet. Neurology|September 5, 2009
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O'Connor, Massimo Filippi, Barry Arnason, et al.
Pageof 1